Monthly SOM230C for Recurrent or Progressive Meningioma

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

December 31, 2011

Study Completion Date

January 31, 2016

Conditions
Meningioma
Interventions
DRUG

SOM230C

Injection in the buttocks every 28 days

Trial Locations (8)

10065

Memorial Sloan Kettering Cancer Center, New York

27157

Wake Forest University Baptist Medical Center, Winston-Salem

27710

Duke University Medical Center, Preston Robert Tisch Brain Tumor Center, Durham

60611

Northwestern University, Chicago

90048

Cedars-Sinai Medical Center, Los Angeles

02114

Massachusetts General Hospital, Boston

02115

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

Brigham and Women's Hospital

OTHER

collaborator

Massachusetts General Hospital

OTHER

collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

Memorial Sloan Kettering Cancer Center

OTHER

collaborator

Wake Forest University Health Sciences

OTHER

collaborator

Duke University

OTHER

collaborator

Cedars-Sinai Medical Center

OTHER

collaborator

Northwestern University

OTHER

collaborator

Novartis

INDUSTRY

lead

Patrick Y. Wen, MD

OTHER